ATRA News

Five initial public offerings collectively raised $1.3 billion during the past week, bringing the year's total to 228 IPOs and $73.5 billion raised, a 35% increase over this time last year by deal count and an 84% increase by proceeds. The S&P 500 had the largest 3-day slide since 2011 while the VIX volatility index leapt above 25 and the IPO market responded with postponed...read more

Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, raised $55 million by offering 5 million shares at $11, below the range of $14 to $16. Atara Biotherapeutics plans to list on the NASDAQ under the symbol ATRA. Atara Biotherapeutics initially filed confidentially on 4/10/2014. Goldman Sachs and Citi acted as lead managers...read more

Seven initial public offerings are expected to raise $1.7 billion in the upcoming week. Four IPOs are biotechs, including Forward Pharma, which could be the year's largest (and 60th), and three others in early stages of development. Consolidated fiber optic network Zayo Group is expected raise $650 million to be the week's largest deal. We should also see the IPOs of midstream...read more

Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, announced terms for its IPO on Tuesday. The Brisbane, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, it would command a fully diluted market value of $305 million. Atara...read more